Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences CellTech India 2015

Venkatesha Venkatasubbaiah's Biography

Venkatesha Venkatasubbaiah, Independent Consultant, Piramal Life Sciences Ltd

Dr. Venkatesh obtained Masters degree in Pharmacology from Rajiv Gandhi University of Health Sciences, Bangalore and received Ph.D degree in cancer research from Kasturba Medical College in Manipal University in 2006. Later he pursued postdoctoral research in the United States of America in the areas of carcinogenesis and cancer stem cells from the University of Iowa and University of Michigan, respectively. He returned to India and joined Piramal Life Sciences Ltd. in 2011 and contributed to the progress of several projects in cancer drug discovery and drug development in a multidisciplinary environment. He has started a new drug discovery program and also established collaborations with leading oncologists. Dr. Venkatesh has written several original research articles that were published in the international peer-reviewed journals (Pubmed link) and he has also trained scientists in the laboratory and mentored research projects of graduate students. Dr. Venkatesh is interested making positive impact on people suffering from cancer by collaborating with oncologists to understand the current clinical needs for the discovery and development of tenable therapeutic options. Click to contact Dr. Venkatesh by LinkedIn or email.

Venkatesha Venkatasubbaiah Image

Sensitization of Pancreatic Cancer Stem Cells to Gemcitabine by Chk1 Inhibition

Tuesday, 3 March 2015 at 16:20

Add to Calendar ▼2015-03-03 16:20:002015-03-03 17:20:00Europe/LondonSensitization of Pancreatic Cancer Stem Cells to Gemcitabine by Chk1 InhibitionCellTech India 2015 in Bangalore, IndiaBangalore,

This Presentation will focus on the how Chk1 Inhibition sensitizes Pancreatic Stem Cells and Tumours to Gemcitabine. Further, it will also discuss about the finding how Chk1-mediated DNA damage response was greater in stem cells than in non–stem cells which  makes Chk1 a potential therapeutic target for improving pancreatic cancer therapy.

Add to Calendar ▼2015-03-02 00:00:002015-03-03 00:00:00Europe/LondonCellTech India 2015CellTech India 2015 in Bangalore, IndiaBangalore,